Grail Launches Clinical Trial for Early Detection of Breast Cancer

This post was originally published on this site

Original Post from GeneomeWeb

NEW YORK (GenomeWeb) – Grail said today that it has begun a clinical trial, STRIVE, for its next-generation sequencing-based blood test for early-stage cancer detection. The firm will collaborate with the Mayo Clinic and Sutter Health to enroll up to 120,000 women at the time when they receive a mammogram. The goal will be to train and validate the test.

The STRIVE study will enroll women at the Mayo and throughout the Sutter Health system in Northern California.

“In order to develop and validate a blood test for the early detection of breast cancer, we need the participation of up to 120,000 women,” Anne-Renee Hartman Grail’s head of clinical development, said in a statement.

The STRIVE study is one of several that Grail is planning. Last December, Grail launched its Circulating Cell-free Genome Atlas (CCGA) study to profile both patients with and without cancer using its NGS approach. The goal of that study is to train Grail’s test to recognize patterns that indicate a developing a tumor.

“I am excited to be part of this initiative to apply new technology to the possibility of detecting breast cancer, and other cancers, at earlier stages,” Steven Cummings, senior scientist at California Pacific


Leave a comment

Your email address will not be published.